Spy­Biotech cash­es in on Serum In­sti­tute deal, net­ting $32.5M round for its 'su­per­glue' VLP vac­cine tech

Rough­ly five months af­ter part­ner­ing with the Serum In­sti­tute of In­dia to de­vel­op Covid-19 vac­cines, Spy­Biotech is ready for its next big thing.

The British biotech pulled in a $32.5 mil­lion Se­ries A round last week, fun­nel­ing the suc­cess of its col­lab­o­ra­tion in­to a ven­ture-cap­i­tal raise. Spy­Biotech is plan­ning to de­vel­op its VLP vac­cine plat­form with the cash, but CEO Su­mi Biswas told End­points News that could go in any num­ber of di­rec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER